Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Following people with Familial Mediterranean Fever or Still's Disease who take canakinumab

Observes how people with these conditions fare after at least 6 months on canakinumab.

Plain-language title generated from the registry record
Registry title: A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Key facts

Where
Basel, SwitzerlandSee the site

Where in Switzerland

  • NovartisBasel, SwitzerlandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Novartis Pharmaceuticals
Trial code
NCT07517250
Record updated
9 June 2026
Original description
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]) that received canakinumab for at least 6 months.Read full original descriptionShow less

Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]) that received canakinumab for at least 6 months.

Inclusion: Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD); Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

Exclusion: Patients Aged <2 Years (24 Months) at Index Date.

ClinicalTrials.gov NCT07517250